CAJ | 학술논문

目的探讨人类疱疹病毒7型(HHV-7)感染在药疹发病中的作用.方法收集50例药疹患者(其中重型药疹15例)及50例健康人外周血,采用PCR检测外周血单一核细胞中HHV-7 DNA特异性片段;酶联免疫吸附试验(ELISA)检测血清HHV-7 IgM水平.结果 50例药疹患者HHV-7 DNA阳性率(82.00％,41例)高于健康对照组(62.00％,31例),两组差异有统计学意义(x2=4.96,P＜0.05);重型药疹患者(93.33％,14/15)、轻型药疹患者(77.14％,27/35)及健康对照组HHV-7 DNA阳性率差异有统计学意义(x2=6.32,P＜0.05),其中重型组高于对照组(q=3.50,P＜0.05);重型药疹患者急性期与恢复期HHV-7 DNA阳性率差异无统计学意义(P＞0.05).药疹患者HHV-7 IgM水平(69.3190±25.2897 ng/L)高于健康对照组(59.7853±22.4382 ng/L,t=1.99,P＜0.05);轻型药疹(65.4791±21.3261 ng/L)、重型药疹(74.3407±31.4112 ng/L)及健康对照组间差异均无统计学意义(均P＞ 0.05).HHV-7 DNA阳性与阴性药疹患者HHV-7特异性IgM水平(分别为63.7481±27.2391 ng/L、65.5802±36.2584 ng/L)差异无统计学意义(P＞0.05).结论药疹患者中存在HHV-7活动性感染,HHV-7感染可能是药疹发病或加重的因素.
목적 탐토인류포진병독7형(HHV-7)감염재약진발병중적작용.방법 수집50례약진환자(기중중형약진15례)급50례건강인외주혈,채용PCR검측외주혈단일핵세포중HHV-7 DNA특이성편단;매련면역흡부시험(ELISA)검측혈청HHV-7 IgM수평.결과 50례약진환자HHV-7 DNA양성솔(82.00％,41례)고우건강대조조(62.00％,31례),량조차이유통계학의의(x2=4.96,P＜0.05);중형약진환자(93.33％,14/15)、경형약진환자(77.14％,27/35)급건강대조조HHV-7 DNA양성솔차이유통계학의의(x2=6.32,P＜0.05),기중중형조고우대조조(q=3.50,P＜0.05);중형약진환자급성기여회복기HHV-7 DNA양성솔차이무통계학의의(P＞0.05).약진환자HHV-7 IgM수평(69.3190±25.2897 ng/L)고우건강대조조(59.7853±22.4382 ng/L,t=1.99,P＜0.05);경형약진(65.4791±21.3261 ng/L)、중형약진(74.3407±31.4112 ng/L)급건강대조조간차이균무통계학의의(균P＞ 0.05).HHV-7 DNA양성여음성약진환자HHV-7특이성IgM수평(분별위63.7481±27.2391 ng/L、65.5802±36.2584 ng/L)차이무통계학의의(P＞0.05).결론 약진환자중존재HHV-7활동성감염,HHV-7감염가능시약진발병혹가중적인소.
Objective To investigate the role of human herpesvirus type 7 (HHV-7) in the development of drug eruptions.Methods Venous blood samples were collected from 35 patients with mild drug eruptions at acute stage,15 patients with severe drug eruptions at both acute stage and remission stage,as well as 50 healthy human controls.PCR was performed to detect HHV-7 DNA in peripheral blood mononuclear cells (PBMCs),and enzymelinked immunosorbent assay (ELISA) to determine the titer of anti-HHV-7 IgM antibody in serum.Statistical analysis was carried out by t test,one way analysis of variance,Chi-square test and q test.Results The detection rate of HHV-7 DNA was significantly higher in these patients with drug eruptions than in the healthy controls (82.00％ (41/50) vs.62.00％ (31/50),x2 =4.96,P ＜ 0.05),different among patients with severe drug eruptions (93.33％ (14/15)),patients with mild drug eruptions (77.14％ (27/35)) and the healthy controls (x2 =6.32,P ＜ 0.05),higher in the patients with severe drug eruptions than in the healthy controls (q =3.50,P ＜ 0.05),but not significantly different between the patients with severe drug eruptions at acute stage and those at remission stage (73.33％(11/15),P ＞ 0.05).The anti-HHV-7 IgM antibody titer was significantly increased in the patients with drug eruptions compared with the healthy controls ((69.319 0 ± 25.289 7) ng/L vs.(59.785 3 ± 22.438 2) ng/L,t =1.99,P ＜ 0.05),but no significant difference was observed among the patients with severe drug eruptions (74.340 7 ±31.411 2) ng/L),patients with mild drug eruptions ((65.479 1 ± 21.326 1) ng/L) and healthy controls (P ＞ 0.05) or between HHV-7 DNA-positive patients ((63.748 1 ± 27.239 1) ng/L) and-negative patients ((65.580 2 ± 36.258 4) ng/L,P ＞ 0.05).Conclusions Active HHV-7 infection exists in patients with drug eruptions,and may be associated with the development and aggravation of this entity.